Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Beta Bionics (Nasdaq: BBNX) announced management will present at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am ET. A live audio webcast will be available on the company’s investor site and archived for later replay.
Positive
- None.
Negative
- None.
News Market Reaction – BBNX
On the day this news was published, BBNX declined 5.51%, reflecting a notable negative market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $34M from the company's valuation, bringing the market cap to $578M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BBNX fell 5.51% while key medical device peers like AHCO (+1.52%), IART (+0.17%), ESTA (+0.16%), and INMD (+0.21%) were modestly positive. Only TNDM appeared in a momentum scan, down 1.19%, suggesting BBNX’s move was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-02-17 | Earnings results | Positive | +0.2% | Reported strong 2025 growth and issued 2026 revenue and margin guidance. |
| 2026-01-08 | Preliminary earnings | Positive | +1.6% | Released preliminary Q4 2025 topline results with strong sales growth metrics. |
| 2025-12-08 | Earnings preview | Neutral | -3.6% | Announced plan to pre-release Q4 2025 topline results and meet investors. |
| 2025-11-03 | Investor conferences | Neutral | +0.4% | Outlined participation in Wolfe Research and Piper Sandler healthcare conferences. |
| 2025-10-28 | Earnings results | Positive | +2.2% | Reported strong Q3 2025 growth, higher guidance, and improved gross margin. |
Recent earnings and conference updates have generally seen modest positive or mixed price reactions, with no strong pattern of selling on good news.
This announcement adds another investor-focused event to Beta Bionics’ communication cadence. In late 2025, the company reported strong Q3 results with raised full‑year guidance and later pre‑announced Q4 strength, followed by full 2025 results showing $100.3M revenue and 2026 guidance of $130M–$135M. Prior conference participation in November–December 2025 saw small positive stock moves. Today’s TD Cowen appearance continues that pattern of regular investor outreach following material financial updates.
Market Pulse Summary
The stock moved -5.5% in the session following this news. A negative reaction despite a routine conference appearance would fit a backdrop where the stock already traded well below its 200-day MA and 52-week high. While recent earnings updates were received constructively, prior news also showed occasional downside moves. Investors reviewing such a decline might weigh the longer-term growth trajectory against existing technical weakness and sensitivity to headlines.
AI-generated analysis. Not financial advice.
IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD Cowen’s 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am Eastern Time (7:30 am Pacific Time).
A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay following the event.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Karen Hynes
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
FAQ
When will Beta Bionics (BBNX) present at the TD Cowen 46th Annual Health Care Conference?
How can investors listen to the Beta Bionics (BBNX) presentation on March 4, 2026?
Will the Beta Bionics (BBNX) presentation at TD Cowen be available after the live event?
What time is the Beta Bionics (BBNX) presentation for Pacific Time viewers on March 4, 2026?
Where on Beta Bionics’ site will the TD Cowen conference webcast be posted?
Who will present for Beta Bionics (BBNX) at the TD Cowen conference on March 4, 2026?
